Inflammation Research Network and Smooth Muscle Research Group, Snyder Institute for Chronic Diseases, Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Am J Physiol Gastrointest Liver Physiol. 2013 Mar 15;304(6):G623-34. doi: 10.1152/ajpgi.00392.2012. Epub 2012 Dec 28.
Mesenteric lymphatic vessels actively transport lymph, immune cells, fat, and other macromolecules from the intestine via a rhythmical contraction-relaxation process called lymphatic pumping. We have previously demonstrated that mesenteric lymphatic pumping was compromised in the guinea pig model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced ileitis, corroborating clinical and experimental observations of a dilated and/or obstructed phenotype of these vessels in inflammatory bowel disease. Many mediators released during the inflammatory process have been shown to alter lymphatic contractile activity. Among them, nitric oxide (NO), an inflammatory mediator abundantly released during intestinal inflammation, decreases the frequency of lymphatic contractions through activation of ATP-sensitive potassium (K(ATP)) channels. The objective of this study was to investigate the role of NO and K(ATP) channels in the lymphatic dysfunction observed in the guinea pig model of TNBS-induced ileitis. Using quantitative real-time PCR, we demonstrated that expression of Kir6.1, SUR2B, and inducible NO synthase (iNOS) mRNAs was significantly upregulated in TNBS-treated animals. Pharmacological studies performed on isolated, luminally perfused mesenteric lymphatic vessels showed that the K(ATP) channels blocker glibenclamide, the selective iNOS inhibitor 1400W, and the guanylyl cyclase inhibitor ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one) significantly improved lymphatic pumping in quiescent lymphatic vessels from TNBS-treated animals. Membrane potential measurement with intracellular microelectrodes revealed that vessels from TNBS-treated animals were hyperpolarized compared with their sham counterpart and that the hyperpolarization was significantly attenuated in the presence of glibenclamide and ODQ. Our findings suggest that NO and K(ATP) play a major role in the lymphatic contractile dysfunction that occurred as a consequence of the intestinal inflammation caused by TNBS.
肠系膜淋巴管通过一种称为淋巴泵的节律性收缩-松弛过程,主动将淋巴、免疫细胞、脂肪和其他大分子从肠道中运输。我们之前已经证明,在 2,4,6-三硝基苯磺酸(TNBS)诱导的回肠炎的豚鼠模型中,肠系膜淋巴泵受到了损害,这与这些血管在炎症性肠病中扩张和/或阻塞表型的临床和实验观察结果一致。在炎症过程中释放的许多介质已被证明会改变淋巴的收缩活性。其中,一氧化氮(NO)是肠道炎症中大量释放的炎症介质,通过激活三磷酸腺苷(ATP)敏感性钾(K(ATP))通道,降低了淋巴收缩的频率。本研究的目的是研究 NO 和 K(ATP) 通道在 TNBS 诱导的回肠炎豚鼠模型中观察到的淋巴功能障碍中的作用。通过定量实时 PCR,我们证明了 Kir6.1、SUR2B 和诱导型一氧化氮合酶(iNOS)mRNA 的表达在 TNBS 处理的动物中显著上调。在分离的、腔内灌注的肠系膜淋巴血管上进行的药理学研究表明,K(ATP) 通道阻滞剂格列本脲、选择性 iNOS 抑制剂 1400W 和鸟苷酸环化酶抑制剂 ODQ(1H-[1,2,4]恶二唑[4,3-a]喹喔啉-1-酮)显著改善了 TNBS 处理动物的静息淋巴血管的淋巴泵功能。用细胞内微电极测量膜电位表明,与假手术对照相比,来自 TNBS 处理动物的血管发生超极化,并且格列本脲和 ODQ 的存在显著减弱了超极化。我们的发现表明,NO 和 K(ATP) 在 TNBS 引起的肠道炎症导致的淋巴收缩功能障碍中起主要作用。